Karyopharm Therapeutics Inc.

NASDAQ:KPTI

Biotechnology

Healthcare
$7.01 -3.62%

-$0.34 today

Market cap
$158.87M
Beta
0.82
P/E (TTM)
-1.0
EPS (TTM)
-$8.86
52W Low $3.65High $10.99

Volume 0.67M

Average 0.85M

Returns on capital

Karyopharm Therapeutics Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

66.9%

avg 22.5%

ROIC

-236.6%

avg -86.8%

ROA

-180.8%

avg -67.6%

Analysis

ROE is currently the strongest return metric at 66.9% versus its period average of 22.5%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Reshma Rangwala

Executive Vice President, Chief Medical Officer & Head of ResearchUSD 1.82M4856.83K0.25%

Sharon Shacham

Co-Founder & Chairman of Scientific Advisory BoardUSD 1.4M5690.00K0.40%

Richard A. Paulson

President, Chief Executive Officer & DirectorUSD 1.24M59269.75K1.19%

Stuart Poulton

Executive Vice President & Chief Development OfficerUSD 971.55K5394.82K0.42%

Lori A. Macomber

Executive Vice President, Chief Financial Officer & TreasurerUSD 712.68K55——

Michael J. Mano

Executive VP, Chief Legal Officer & SecretaryUSD 625.08K49——

Brendan Twohig Strong

Senior Vice President of Investor Relations————

Brian Austad

Senior Vice President of Pharmaceutical Sciences————

James Accumanno

Chief Compliance Officer————

Kristin Abate

Vice President, Chief Accounting Officer & Assistant Treasurer——23.80K0.11%

Lisa DiPaolo

Executive Vice President & Chief Human Resource Officer————

Compensation is shown in the reported currency; data updated Jul 25, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 14, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

16

$342,668.85

Net Transaction Value

−$342,668.85

Net selling

Most Active

Poulton Stuart

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
May 14, 26

Mano Michael

Direct

Sell$2.5K
May 14, 26

Poulton Stuart

Direct

Sell$3.8K
May 14, 26

Rangwala Reshma

Direct

Sell$3.9K
May 14, 26

Cheng Sohanya Roshan

Direct

Sell$3.1K
May 14, 26

Abate Kristin

Direct

Sell$503.5
May 14, 26

Paulson Richard A.

Direct

Sell$20.9K
Apr 21, 26

Rangwala Reshma

Direct

Sell$4K
Mar 2, 26

Poulton Stuart

Direct

Sell$48K
Mar 2, 26

Mano Michael

Direct

Sell$33.2K
Mar 2, 26

Cheng Sohanya Roshan

Direct

Sell$43.3K

1–10 of 16

Summary

Insiders reported 0 buys worth $0.00 and 16 sells worth $342,668.85 over the last 12 months. That adds up to net selling of $342,668.85. Poulton Stuart was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-2.4%
+33.2% (5yr)3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Recent growth has been strongest in Revenue at -2.4% over three years. Forward estimates point to Revenue at +33.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Karyopharm Therapeutics Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about KPTI's management, answered from reported figures.

Who manages KPTI?

Karyopharm Therapeutics Inc. (KPTI) lists 11 active executives. The top listed executive is Reshma Rangwala, Executive Vice President, Chief Medical Officer & Head of Research.

Are KPTI insiders buying or selling?

Recent insider activity shows net buying of $79,308.15.